Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials

A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG

(2014) C. H. Smorenburg et al.   ANNALS OF ONCOLOGY

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

(2014) J. Baselga et al.   ANNALS OF ONCOLOGY

Epidemiology of Breast Cancer

(2014) Kristen A. Ban et al.   Surgical Oncology Clinics of North America

Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: The CASA randomized trial

(2013) Diana Crivellari et al.   BREAST

Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group

(2013) M.E. Hamaker et al.   BREAST

A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study

(2011) Patrizia Vici et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II)

(2010) M. S. Rosati et al.   ANNALS OF ONCOLOGY

Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)

(2010) C. Rochlitz et al.   ANNALS OF ONCOLOGY

Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study

(2010) Emilio Alba et al.   BREAST CANCER RESEARCH AND TREATMENT

A Phase II Randomized Crossover Study of Liposomal Doxorubicin Versus Weekly Docetaxel in the First-line Treatment of Women With Metastatic Breast Cancer

(2009) Denise A. Yardley et al.   Clinical Breast Cancer

Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study

(2009) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

2009 Updated Method Guidelines for Systematic Reviews in the Cochrane Back Review Group

(2009) Andrea D. Furlan et al.   SPINE

Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial

(2008) Peter Schmid et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Metastatic breast cancer: The role of pegylated liposomal doxorubicin after conventional anthracyclines

(2008) Shailendra Verma et al.   CANCER TREATMENT REVIEWS